Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 70: Line 70:
 
*[[Bavituximab (PGN401)]] '''in clinical trials'''
 
*[[Bavituximab (PGN401)]] '''in clinical trials'''
 
*[[Belagenpumatucel-L (Lucanix)]] '''in clinical trials'''
 
*[[Belagenpumatucel-L (Lucanix)]] '''in clinical trials'''
−
*[[Belinostat (Beleodaq)]] '''FDA Approved 7/3/2014'''
+
*[[Belinostat (Beleodaq)]]
 
*[[Bendamustine (Treanda)]]
 
*[[Bendamustine (Treanda)]]
 
*[[Betrixaban (PRT-054021)]] '''in clinical trials'''
 
*[[Betrixaban (PRT-054021)]] '''in clinical trials'''
Line 81: Line 81:
 
*[[BL22 immunotoxin (CAT-3888)]] '''in clinical trials'''
 
*[[BL22 immunotoxin (CAT-3888)]] '''in clinical trials'''
 
*[[Bleomycin (Blenoxane)]]
 
*[[Bleomycin (Blenoxane)]]
−
*[[Blinatumomab (Blincyto)]] '''FDA Approved 12/3/2014'''
+
*[[Blinatumomab (Blincyto)]]
 
*[[Bortezomib (Velcade)]]
 
*[[Bortezomib (Velcade)]]
 
*[[Bosutinib (Bosulif)]]
 
*[[Bosutinib (Bosulif)]]
Line 104: Line 104:
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[CC-292 (AVL-292)]] '''in clinical trials'''
 
*[[CC-292 (AVL-292)]] '''in clinical trials'''
−
*[[Ceritinib (Zykadia)]] '''FDA approved 4/29/2014'''
+
*[[Ceritinib (Zykadia)]]
 
*[[Cetirizine (Zyrtec)]]
 
*[[Cetirizine (Zyrtec)]]
 
*[[Cetuximab (Erbitux)]]
 
*[[Cetuximab (Erbitux)]]
Line 278: Line 278:
 
*[[Idarubicin (Idamycin)]]
 
*[[Idarubicin (Idamycin)]]
 
*[[Idarucizumab (Praxbind)]] '''FDA approved 10/16/2015'''
 
*[[Idarucizumab (Praxbind)]] '''FDA approved 10/16/2015'''
−
*[[Idelalisib (Zydelig)]] '''FDA approved 7/23/2014'''
+
*[[Idelalisib (Zydelig)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[IMA901]] '''in clinical trials'''
 
*[[IMA901]] '''in clinical trials'''
Line 375: Line 375:
 
*[[Nilutamide (Nilandron)]]
 
*[[Nilutamide (Nilandron)]]
 
*[[Nintedanib (BIBF 1120)]] '''in clinical trials'''  
 
*[[Nintedanib (BIBF 1120)]] '''in clinical trials'''  
−
*[[Nivolumab (Opdivo)]] '''FDA approved 12/22/2014'''
+
*[[Nivolumab (Opdivo)]]
 
*[[Nolatrexed (Thymitaq)]]
 
*[[Nolatrexed (Thymitaq)]]
 
*[[NovoTTF-100A system (Optune)]]
 
*[[NovoTTF-100A system (Optune)]]
Line 391: Line 391:
 
*[[ODM-201]] '''in clinical trials'''
 
*[[ODM-201]] '''in clinical trials'''
 
*[[Ofatumumab (Arzerra)]]
 
*[[Ofatumumab (Arzerra)]]
−
*[[Olaparib (Lynparza)]] '''FDA approved 12/19/2014'''
+
*[[Olaparib (Lynparza)]]
 
*[[Omacetaxine (Synribo)]]
 
*[[Omacetaxine (Synribo)]]
 
*[[Omeprazole (Prilosec)]]
 
*[[Omeprazole (Prilosec)]]
Line 423: Line 423:
 
*[[Peginterferon alfa-2a (Pegasys)]]
 
*[[Peginterferon alfa-2a (Pegasys)]]
 
*[[Peginterferon alfa-2b (Sylatron)]]
 
*[[Peginterferon alfa-2b (Sylatron)]]
−
*[[Pembrolizumab (Keytruda)]] '''FDA approved 9/4/2014'''
+
*[[Pembrolizumab (Keytruda)]]
 
*[[Pemetrexed (Alimta)]]
 
*[[Pemetrexed (Alimta)]]
 
*[[Pentamidine (Nebupent)]]
 
*[[Pentamidine (Nebupent)]]
Line 440: Line 440:
 
*[[Ponatinib (Iclusig)]]
 
*[[Ponatinib (Iclusig)]]
 
*[[Porfimer (Photofrin)]]
 
*[[Porfimer (Photofrin)]]
−
*[[Pracinostat (SB939)]] '''Orphan drug designation 2/27/2014'''
+
*[[Pracinostat (SB939)]]
 
*[[Pralatrexate (Folotyn)]]
 
*[[Pralatrexate (Folotyn)]]
 
*[[Prasugrel (Effient)]]
 
*[[Prasugrel (Effient)]]
Line 465: Line 465:
 
*[[Raloxifene (Evista)]]
 
*[[Raloxifene (Evista)]]
 
*[[Raltitrexed (Tomudex)]]
 
*[[Raltitrexed (Tomudex)]]
−
*[[Ramucirumab (Cyramza)]] '''FDA approved 4/21/2014'''
+
*[[Ramucirumab (Cyramza)]]
 
*[[Ranitidine (Zantac)]]
 
*[[Ranitidine (Zantac)]]
 
*[[Rasburicase (Elitek)]]
 
*[[Rasburicase (Elitek)]]
Line 500: Line 500:
 
*[[Sennosides (Senna)]]
 
*[[Sennosides (Senna)]]
 
*[[SGN-CD19A]] '''in clinical trials'''
 
*[[SGN-CD19A]] '''in clinical trials'''
−
*[[Siltuximab (Sylvant)]] '''FDA approved 4/23/2014'''
+
*[[Siltuximab (Sylvant)]]
 
*[[Sipuleucel-T (Provenge)]]
 
*[[Sipuleucel-T (Provenge)]]
 
*[[Sirolimus (Rapamune)]]
 
*[[Sirolimus (Rapamune)]]
Line 575: Line 575:
 
*[[Vinorelbine (Navelbine)]]
 
*[[Vinorelbine (Navelbine)]]
 
*[[Vismodegib (Erivedge)]]
 
*[[Vismodegib (Erivedge)]]
−
*[[Volasertib (BI 6727)]] '''FDA orphan drug status 4/14/2014'''
+
*[[Volasertib (BI 6727)]]
 
*[[Von Willebrand Factor and factor VIII complex, human]]
 
*[[Von Willebrand Factor and factor VIII complex, human]]
 
*[[Vorinostat (Zolinza)]]
 
*[[Vorinostat (Zolinza)]]
Line 902: Line 902:
 
*[[:Category:Drugs FDA approved in 2014|Drugs FDA approved in 2014]]
 
*[[:Category:Drugs FDA approved in 2014|Drugs FDA approved in 2014]]
 
*[[:Category:Drugs FDA approved in 2015|Drugs FDA approved in 2015]]
 
*[[:Category:Drugs FDA approved in 2015|Drugs FDA approved in 2015]]
 +
*[[:Category:Drugs FDA approved in 2016|Drugs FDA approved in 2016]]
 
</div>
 
</div>
  

Revision as of 01:44, 1 January 2016

Alphabetically

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

J

K

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

V

back to top

W

back to top

X

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).

Cytotoxic Chemotherapy

back to top

Kinase inhibitors

back to top

Endocrine therapy

back to top

Investigational and Discontinued

Biologics

back to top

Supportive Medications

back to top

Radioactive agents

Benign Hematology Medications

back to top

Hematopoietic Growth Factors

back to top

Miscellaneous

back to top

Medications by Cancer Subtype

back to top

Medications by Route of Administration

back to top

Medications by Year of Approval

back to top

Interesting and Helpful Links

back to top

References

  1. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
  2. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=9947"